Piper Jaffray Cuts Price Target on Nuvectra Corporation (NVTR) Following 2Q Revenue Beat
Get Alerts NVTR Hot Sheet
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Piper Jaffray maintained a Neutral rating on Nuvectra Corporation (NASDAQ: NVTR), and cut the price target to $10.00 (from $12.00), following the company's 2Q earnings report. NVTR reported revenue of $2.6M, compared with $2.4M estimates.
Analyst Brooks West commented, "Nuvectra reported 2Q16 revenue of $2.6M vs. our $2.4M as stronger revenues related to NVTR’s partnership with Aleva Neurotherapeutics and volume of component sales from its NeuroNexus subsidiary offset a slower ramp in Algovita SCS ramp versus our model. Management stated that it is focused on the build out of its SCS field force with 28 current active territories and ~10 territories scheduled to complete training by the end of August. This leaves the company on track to have ~50 active territories by the end of 3Q16. That said, we have taken a more conservative approach to our first year Algovita ramp assumptions given the lag in navigating hospital and ASC purchasing departments cited by management along with the natural 3-month progression of patients from identification to permanent implant. We reiterate our N rating, lowering PT to $10 from $12."
For an analyst ratings summary and ratings history on Nuvectra Corporation click here. For more ratings news on Nuvectra Corporation click here.
Shares of Nuvectra Corporation closed at $6.64 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
- Lockheed Martin (LMT) PT Raised to $487 at Deutsche Bank
- Goldman Sachs Downgrades Zhejiang Huayou Cobalt Co Ltd. (603799:CH) to Sell
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Piper Jaffray, Earnings, Brooks WestSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!